Randomized, double-blind, active-controlled study evaluating the safety and immunogenicity of three vaccination schedules and two dose levels of AV7909 vaccine for anthrax post-exposure prophylaxis in healthy adults

• Published in: Vaccine Vol. 34; no. 18; pp. 2096 - 2105
• Main Authors: Hopkins, Robert J., Kalsi, Gurdyal, Montalvo-Lugo, Victor M., Sharma, Mona, Wu, Yukun, Muse, Derek D., Sheldon, Eric A., Hampel, Frank C., Lemiale, Laurence
• Format: Journal Article
• Language: English
• Published: Netherlands Elsevier Ltd 19.04.2016; Elsevier Limited
• Subjects: Adjuvants, Immunologic - administration & dosage; Adult; adults; Allergy and Immunology; Anthrax; Anthrax - prevention & control; Anthrax Vaccines - administration & dosage; Anthrax Vaccines - adverse effects; Anthrax Vaccines - therapeutic use; Antibodies, Bacterial - blood; Antibodies, Neutralizing - blood; Antigens; BioThrax® (Anthrax Vaccine Adsorbed); Blood pressure; CPG 7909; disease control; Double-Blind Method; Drug dosages; etiology; Female; Hispanic Americans; Humans; Immune response; Immunization Schedule; Immunogenicity; Infections; Investigations; Male; Middle Aged; neutralization; neutralizing antibodies; Oligodeoxyribonucleotides - administration & dosage; Post-exposure prophylaxis; Post-Exposure Prophylaxis - methods; Prophylaxis; Safety; Toxins; Urine; vaccination; Vaccine; Vaccines; Young Adult; United States > US; BioThrax® (Anthrax Vaccine Adsorbed); Vaccine; Post-exposure prophylaxis; NCT01770743; Anthrax; CPG 7909; BioThrax ® (Anthrax Vaccine Adsorbed); BioThrax(®) (Anthrax Vaccine Adsorbed)

•AV7909 is a combination of BioThrax® (Anthrax Vaccine Absorbed) and CPG 7909 adjuvant.•AV7909 vaccine is being developed for anthrax post-exposure prophylaxis.•The safety and immunogenicity of 2 doses and 3 vaccine schedules were evaluated.•Immunogenicity results indicate further study of a two dos...